Product Description
Rosuvastatin is used together with diet, weight-loss, and exercise to reduce the risk of heart attack and stroke and to decrease the chance that heart surgery will be needed in people who have heart disease or who are at risk of developing heart disease.
Mechanisms of Action: HMG-CoA Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: AstraZeneca
Company Location: CAMBRIDGE X0 CB2 0AA
Company CEO: Pascal Soriot
Additonal Commercial Interests: Grunenthal
Clinical Description
Countries in Clinic: Australia, Belgium, Brazil, Canada, China, Czech Republic, France, Germany, Italy, Korea, Spain, United Kingdom, United States
Active Clinical Trial Count: 39
Highest Development Phases
Phase 3: Hypercholesterolemia
Phase 1: Anemia|Autoimmune Disease Unspecified|Breast Cancer|COVID-19|Dyslipidemia|Healthy Volunteers|Hyperlipidemia|Influenza, Human|Malaria|Non-Small-Cell Lung Cancer|Obesity|Oncology Solid Tumor Unspecified|Overweight|Severe Acute Respiratory Syndrome|Type 2 Diabetes
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| CA127-1027 | P1 |
Not yet recruiting |
Oncology Solid Tumor Unspecified |
2025-07-31 |
|
| C3421086 | P1 |
Recruiting |
Obesity|Overweight |
2025-04-30 |
|
| D9440C00002 | P1 |
Recruiting |
Healthy Volunteers |
2025-04-11 |
|
| HDM1002-106 | P1 |
Not yet recruiting |
Overweight |
2025-02-01 |